2021 Protein-Tyrosine Phosphatase Inhibitors Pipeline Insight Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Protein-Tyrosine Phosphatase (Ptp) Inhibitors – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Protein-Tyrosine Phosphatase (PTP) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Protein-Tyrosine Phosphatase (PTP) Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Protein-Tyrosine Phosphatase (PTP) Inhibitors.

Protein-Tyrosine Phosphatase (PTP) Inhibitors Emerging Drugs Chapters

This segment of the Protein-Tyrosine Phosphatase (PTP) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Protein-Tyrosine Phosphatase (PTP) Inhibitors Emerging Drugs

JAB-3068: Jacobio Pharmaceuticals

JAB-3068 is a novel protein tyrosine phosphatase inhibitor (PTPi) with independent intellectual property rights. In February 2019, the US Food and Drug Administration (FDA) also awarded JAB-3068 orphan drug designation for the treatment of esophageal cancer, providing substantial support for the drug’s global development for this indication. In May 2020, Jacobio Pharmaceuticals and Abbvie entered into an agreement to develop and commercialize SHP2 inhibitors, including JAB-3068 and JAB-3312, on a worldwide basis.

ERAS-601: Erasca

RAS-601, is a potent, selective oral inhibitor of SHP2, a convergent node for upstream RTK signaling and a critical “on/off switch” that activates GTP-bound RAS signaling. SHP2 also drives tumor cell proliferation and development of resistance. SHP2 inhibitor is designed to block oncogenic signal transduction and delay the onset of resistance, thereby potentially serving as a backbone of combination therapy. It is currently in Phase I stage of development and is being developed by Erasca.

Protein-Tyrosine Phosphatase (PTP) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Protein-Tyrosine Phosphatase (PTP) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Protein-Tyrosine Phosphatase (PTP) Inhibitors

There are approx. 20+ key companies which are developing the therapies for Protein-Tyrosine Phosphatase (PTP) Inhibitors. The companies which have their Protein-Tyrosine Phosphatase (PTP) Inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Jacobio Pharmaceuticals.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Protein-Tyrosine Phosphatase (PTP) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Protein-Tyrosine Phosphatase (PTP) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Protein-Tyrosine Phosphatase (PTP) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Protein-Tyrosine Phosphatase (PTP) Inhibitors drugs.

Protein-Tyrosine Phosphatase (PTP) Inhibitors Report Insights

• Protein-Tyrosine Phosphatase (PTP) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Protein-Tyrosine Phosphatase (PTP) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Protein-Tyrosine Phosphatase (PTP) Inhibitors drugs?
• How many Protein-Tyrosine Phosphatase (PTP) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Protein-Tyrosine Phosphatase (PTP) Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Protein-Tyrosine Phosphatase (PTP) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Protein-Tyrosine Phosphatase (PTP) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jacobio Pharmaceuticals
• Novartis
• Sanofi
• Erasca
• Suzhou Genhouse Bio
• Relay Therapeutics
• Navire

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1zaul3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900